Jane Street’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Jane Street’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,177	Closed	-$2.13K	–	10301
2023 Q4	$2.13K	Sell	20,177 -8,761	-30%	-$1.29K	﹤0.01%	9052
2023 Q3	$6.51K	Hold	28,938	–	–	﹤0.01%	8426
2023 Q2	$7.59K	Sell	28,938 -749	-3%	-$146	﹤0.01%	8462
2023 Q1	$5.34K	Sell	29,687 -1,935	-6%	-$443	﹤0.01%	8802
2022 Q4	$6.32K	Sell	31,622 -2,602	-8%	-$1.12K	﹤0.01%	8829
2022 Q3	$25K	Sell	34,224 -4,316	-11%	-$2.95K	﹤0.01%	9141
2022 Q2	$20K	Buy	38,540 +6,056	+19%	+$3.84K	﹤0.01%	9165
2022 Q1	$29K	Sell	32,484 -3,413	-10%	-$3.8K	﹤0.01%	9846
2021 Q4	$80K	Buy	35,897 +5,821	+19%	+$18.8K	﹤0.01%	9339
2021 Q3	$102K	Buy	+30,076	New	+$107K	﹤0.01%	9284

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jane Street's DNA.WS Position: Q1 2024 in Review

Jane Street sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q1 2024, closing a stake of 20,177 shares — an estimated $2.13K sold.

Jane Street first reported a position in DNA.WS in Q3 2021 and held it in 10 quarters. The position peaked at $102K in Q3 2021. 28 funds tracked by Wall St. Rank hold DNA.WS as of Q1 2024.

Jane Street reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q1 2024 after selling out during the quarter.
Jane Street sold 20,177 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q1 2024, an estimated $2.13K.
Jane Street first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 10 quarters.
Jane Street's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $102K in Q3 2021.
28 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q1 2024.

Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.